842129-23-1

Basic information

• Product Name: N²-(4-(4-methylpiperazin-1-yl)phenyl)-5-nitro-N⁴-phenylpyrimidine-2,4-diamine
• CAS NO: 842129-23-1
• Molecular Weight: 405.459
• Mol File: 842129-23-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N²-(4-(4-methylpiperazin-1-yl)phenyl)-5-nitro-N⁴-phenylpyrimidine-2,4-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: N²-(4-(4-methylpiperazin-1-yl)phenyl)-5-nitro-N⁴-phenylpyrimidine-2,4-diamine(842129-23-1)
• EPA Substance Registry System: N²-(4-(4-methylpiperazin-1-yl)phenyl)-5-nitro-N⁴-phenylpyrimidine-2,4-diamine(842129-23-1)

Safety Data

• Hazardous Substances Data: 842129-23-1(Hazardous Substances Data)

Upstream product

• 16155-03-6 1-methyl-4-(4-nitrophenyl)piperazine 
• 16153-81-4 4-(4-Methyl-piperazino)-anilin 
• 54748-09-3 2-chloro-5-nitro-N-phenylpyrimidin-4-amine 

Downstream Products

• 1414781-16-0 C₂₈H₂₈N₈ 

Relevant articles and documents

Structural optimization and structure-activity relationships of N 2-(4-(4-methylpiperazin-1-yl)phenyl)- N 8-phenyl-9 H -purine-2,8-diamine derivatives, a new class of reversible kinase inhibitors targeting both EGFR-activating and resistance mutations

This paper describe the structural optimization of a hit compound, N 2-(4-(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H-purine- 2,8-diamine (1), which is a reversible kinase inhibitor targeting both EGFR-activating and drug-resistance (T790M) mutations but has poor binding affinity. Structure-activity relationship studies led to the identification of 9-cyclopentyl-N2-(4-(4-methylpiperazin-1-yl)phenyl)-N 8-phenyl-9H-purine-2,8-diamine (9e) that exhibits significant in vitro antitumor potency against the non-small-cell lung cancer (NSCLC) cell lines HCC827 and H1975, which harbor EGFR-activating and drug-resistance mutations, respectively. Compound 9e was further assessed for potency and selectivity in enzymatic assays and in vivo anti-NSCLC studies. The results indicated that compound 9e is a highly potent kinase inhibitor against both EGFR-activating and resistance mutations and has good kinase spectrum selectivity across the kinome. In vivo, oral administration of compound 9e at a dose of 5 mg/kg caused rapid and complete tumor regression in a HCC827 xenograft model, and an oral dose of 50 mg/kg initiated a considerable antitumor effect in an H1975 xenograft model.